ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorStanford University
About this trial
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Eligibility criteria
Qualifiers
Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available
Disqualifiers
Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
Exclude one-time consultation type of new patients.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
13Argentina
Hospital Italiano de Buenos Aires Buenos Aires Argentina
Australia
Peter MacCallum Cancer Center, Melbourne Australia
Brazil
University of Sao Paulo Medical School São Paulo Brazil
China
Peking University First Hospital Beijing China
Sponsors and collaborators
Stanford University
Lead sponsor
Source ClinicalTrials.gov